Read More Pharma Industry News How Spruce Biosciences’ tralesinidase alfa could become the first disease-modifying therapy for Sanfilippo syndrome type B Find out how Spruce Biosciences is redefining enzyme replacement therapy with its FDA-designated tralesinidase alfa for Sanfilippo syndrome type B. bySoujanya RaviOctober 6, 2025